Literature DB >> 18317350

Plasmin enzyme-assisted vitrectomy for primary and reoperated eyes with stage 5 retinopathy of prematurity.

Wei-Chi Wu1, Kimberly A Drenser, Michael Lai, Antonio Capone, Michael T Trese.   

Abstract

PURPOSE: To review the surgical outcome of plasmin enzyme-assisted vitreoretinal surgery in managing stage 5 retinopathy of prematurity (ROP).
METHODS: A retrospective, consecutive interventional cases series of 80 eyes (68 patients) with stage 5 ROP, treated with autologous or maternal plasmin enzyme-assisted vitreoretinal surgery, were reviewed. All study patients underwent surgery between 1995 and 2004 with plasmin enzyme-assisted vitreoretinal surgery. Thirty-eight eyes had previous vitreous surgery without retinal breaks (Group 1). Fifteen eyes had previous vitreous surgery with retinal breaks (Group 2). Twenty eyes received previous laser, and/or cryotherapy, and/or scleral buckling, but no vitrectomy (Group 3). Seven eyes did not receive any treatment previously (Group 4).
RESULTS: Postoperative anatomic outcome, functional results, and surgical complications in each group of eyes at an average follow-up of 49 months were recorded. Following surgery of all 80 eyes, anatomic success was achieved in 68.8%. Six eyes (7.5%) achieved 20/60 to 20/600 vision. Fifty-nine eyes (73.8%) achieved vision worse than 20/600 to light perception. Eleven eyes (13.8%) achieved no light perception. Visual results were uncertain in 4 eyes (5%) because of the inability to measure reliably.
CONCLUSION: Plasmin enzyme-assisted vitrectomy in eyes with and without previous vitrectomy surgery can achieve visual improvement in stage 5 ROP. Early intervention with vitreous surgery for stage 4A ROP will achieve better anatomic and visual results and reduce the number of children with stage 5 ROP.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18317350     DOI: 10.1097/IAE.0b013e318158ea0e

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  10 in total

1.  [Pharmacological vitreolysis].

Authors:  C Haritoglou; A Kampik
Journal:  Ophthalmologe       Date:  2013-10       Impact factor: 1.059

2.  Intravitreal bevacizumab in retinopathy of prematurity: an interventional case series.

Authors:  Ramak Roohipoor; Hamed Ghasemi; Fariba Ghassemi; Reza Karkhaneh; Mohammad Riazi-Esfahani; Mehdi Nili-Ahmadabadi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-04-15       Impact factor: 3.117

3.  Emerging nonsurgical methods for the treatment of vitreomacular adhesion: a review.

Authors:  Eric W Schneider; Mark W Johnson
Journal:  Clin Ophthalmol       Date:  2011-08-18

4.  Pharmacologic vitreolysis.

Authors:  Hossein Nazari; Mehdi Modarres-Zadeh; Arash Maleki
Journal:  J Ophthalmic Vis Res       Date:  2010-01

Review 5.  Ocriplasmin for symptomatic vitreomacular adhesion: an evidence-based review of its potential.

Authors:  Su Jeong Song; William E Smiddy
Journal:  Core Evid       Date:  2014-03-21

Review 6.  Profile of ocriplasmin and its potential in the treatment of vitreomacular adhesion.

Authors:  Francisco R Stefanini; Maurício Maia; Paulo Falabella; Marcel Pfister; Moritz Niemeyer; Amir H Kashani; Mark S Humayun; Michael J Koss
Journal:  Clin Ophthalmol       Date:  2014-05-06

7.  Lens subluxation after plasmin and SF6 injections in rabbit eyes.

Authors:  Wei-Chi Wu; Chi-Hsien Liu; Nan-Kai Wang; Kwan-Jen Chen; Tun-Lu Chen; Yih-Shiou Hwang; Pei-Ju Liao; Lien-Min Li; Chi-Chun Lai
Journal:  PLoS One       Date:  2014-11-14       Impact factor: 3.240

Review 8.  Ocriplasmin for vitreoretinal diseases.

Authors:  Irena Tsui; Carolyn K Pan; Ehsan Rahimy; Steven D Schwartz
Journal:  J Biomed Biotechnol       Date:  2012-10-14

9.  Efficient vitreolysis by combining plasmin and sulfur hexafluoride injection in a preclinical study in rabbit eyes.

Authors:  Wei-Chi Wu; Chi-Hsien Liu; Chih-Chun Chen; Nan-Kai Wang; Kwan-Jen Chen; Tun-Lu Chen; Yih-Shiou Hwang; Lien-Min Li; Chi-Chun Lai
Journal:  Mol Vis       Date:  2012-09-19       Impact factor: 2.367

10.  Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization.

Authors:  Frank S Ong; Jane Z Kuo; Wei-Chi Wu; Ching-Yu Cheng; Wendell-Lamar B Blackwell; Brian L Taylor; Wayne W Grody; Jerome I Rotter; Chi-Chun Lai; Tien Y Wong
Journal:  J Pers Med       Date:  2013
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.